Boeckh, M, Leisenring, W, Riddell, SR, et al. Late cytomegalovirus disease and mortality in recipients of allogeneic hematopoietic stem cell transplants: importance of viral load and T cell immunity. Blood. 2003;101(2):407–414.CrossRefGoogle ScholarPubMed

Brunstein, CG, Weisdorf, DJ, DeFor, T, et al. Marked increased risk of Epstein–Barr virus-related complications with the addition of antithymocyte globulin to a nonmyeloablative conditioning prior to unrelated umbilical cord blood transplantation. Blood. 2006;108(8):2874–2880.CrossRefGoogle ScholarPubMed

Myers, GD, Krance, RA, Weiss, H, et al. Adenovirus infection rates in pediatric recipients of alternate donor allogeneic bone marrow transplants receiving either antithymocyte globulin (ATG) or alemtuzumab (Campath). Bone Marrow Transplant. 2005;36(11):1001–1008.CrossRefGoogle ScholarPubMed

Neofytos, D, Horn, D, Anaissie, E, et al. Epidemiology and outcome of invasive fungal infection in adult hematopoietic stem cell transplant recipients: analysis of Multicenter Prospective Antifungal Therapy (PATH) Alliance registry. Clin Infect Dis. 2009;48(3):265–273.CrossRefGoogle ScholarPubMed

Avery, R. Update in management of Ganciclovir-resistant cytomegalovirus infection. Curr Opin Infect Dis. 2008;21:433–437.CrossRefGoogle ScholarPubMed

Biron, KK. Antiviral drugs for cytomegalovirus diseases. Antiviral Res. 2006;71(2–3):154–163.CrossRefGoogle ScholarPubMed

Nichols, WG, Corey, L, Gooley, T, et al. Rising pp65 antigenemia during preemptive anticytomegalovirus therapy after allogeneic hematopoietic stem cell transplantation: risk factors, correlation with DNA load, and outcomes. Blood. 2001;97(4):867–874.CrossRefGoogle ScholarPubMed

Ljungman, P, Deliliers, GL, Platzbecker, U, et al. Cidofovir for cytomegalovirus infection and disease in allogeneic stem cell transplant recipients. The Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation. Blood. 2001;97(2):388–392.CrossRefGoogle ScholarPubMed

Kuehnle, I, Huls, MH, Liu, Z, et al. CD20 monoclonal antibody (rituximab) for therapy of Epstein–Barr virus lymphoma after hemopoietic stem-cell transplantation. Blood. 2000;95(4):1502–1505.CrossRefGoogle ScholarPubMed

Papadopoulos, EB, Ladanyi, M, Emanuel, D, et al. Infusions of donor leukocytes to treat Epstein–Barr virus-associated lymphoproliferative disorders after allogeneic bone marrow transplantation. N Engl J Med. 1994;330(17):1185–1191.CrossRefGoogle ScholarPubMed

Slezak, SL, Bettinotti, M, Selleri, S, Adams, S, Marincola, FM, Stroncek, DF. CMV pp65 and IE-1 T cell epitopes recognized by healthy subjects. J Transl Med. 2007;5:17.CrossRefGoogle ScholarPubMed

Leen, AM, Christin, A, Khalil, M, et al. Identification of hexon-specific CD4 and CD8 T cell epitopes for vaccine and immunotherapy. J Virol. 2008;82(1):546–554.CrossRefGoogle ScholarPubMed

Bollard, CM, Rooney, CM, Heslop, HE. T-cell therapy in the treatment of post-transplant lymphoproliferative disease. Nat Rev Clin Oncol. 2012;9(9):510–519.CrossRefGoogle ScholarPubMed

Hanley, PJ, Cruz, CR, Savoldo, B, et al. Functionally active virus-specific T cells that target CMV, adenovirus, and EBV can be expanded from naive T-cell populations in cord blood and will target a range of viral epitopes. Blood. 2009;114(9):1958–1967.CrossRefGoogle Scholar

Leen, AM, Myers, GD, Sili, U, et al. Monoculture-derived T lymphocytes specific for multiple viruses expand and produce clinically relevant effects in immunocompromised individuals. Nat Med. 2006;12(10):1160–1166.CrossRefGoogle ScholarPubMed

Sili, U, Huls, MH, Davis, AR, et al. Large-scale expansion of dendritic cell-primed polyclonal human cytotoxic T-lymphocyte lines using lymphoblastoid cell lines for adoptive immunotherapy. J Immunother. 2003;26(3):241–256.CrossRefGoogle ScholarPubMed

Kern, F, Faulhaber, N, Frommel, C, et al. Analysis of CD8 T cell reactivity to cytomegalovirus using protein-spanning pools of overlapping pentadecapeptides. Eur J Immunol. 2000;30(6):1676–1682.3.0.CO;2-V>CrossRefGoogle ScholarPubMed

Hanley, PJ, Shaffer, DR, Cruz, CR, et al. Expansion of T cells targeting multiple antigens of cytomegalovirus, Epstein–Barr virus and adenovirus to provide broad antiviral specificity after stem cell transplantation. Cytotherapy. 2011;13(8):976–986.CrossRefGoogle ScholarPubMed

Kalos, M, June, CH. Adoptive T cell transfer for cancer immunotherapy in the era of synthetic biology. Immunity. 2013;39(1):49–60.CrossRefGoogle ScholarPubMed

Sellar, RS, Peggs, KS. The role of virus-specific adoptive T-cell therapy in hematopoietic transplantation. Cytotherapy. 2012;14(4):391–400.CrossRefGoogle ScholarPubMed

Hansen, SG, Powers, CJ, Richards, R, et al. Evasion of CD8+ T cells is critical for superinfection by cytomegalovirus. Science. 2010;328(5974):102–106.CrossRefGoogle ScholarPubMed

Neudorfer, J, Schmidt, B, Huster, KM, et al. Reversible HLA multimers (Streptamers) for the isolation of human cytotoxic T lymphocytes functionally active against tumor- and virus-derived antigens. J Immunol Methods. 2007;320(1–2):119–131.CrossRefGoogle ScholarPubMed

Schmitt, A, Tonn, T, Busch, DH, et al. Adoptive transfer and selective reconstitution of streptamer-selected cytomegalovirus-specific CD8+ T cells leads to virus clearance in patients after allogeneic peripheral blood stem cell transplantation. Transfusion. 2011;51(3):591–599.CrossRefGoogle ScholarPubMed

Bollard, CM, Kuehnle, I, Leen, A, Rooney, CM, Heslop, HE. Adoptive immunotherapy for posttransplantation viral infections. Biol Blood Marrow Transplant. 2004;10(3):143–155.CrossRefGoogle ScholarPubMed

Gattinoni, L, Klebanoff, CA, Palmer, DC, et al. Acquisition of full effector function in vitro paradoxically impairs the in vivo antitumor efficacy of adoptively transferred CD8+ T-cells. J Clin Invest. 2005;115(6):1616–1626.CrossRefGoogle ScholarPubMed

Heslop, HE, Slobod, KS, Pule, MA, et al. Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients. Blood. 2010;115(5):925–935.CrossRefGoogle ScholarPubMed

Melenhorst, JJ, Leen, AM, Bollard, CM, et al. Allogeneic virus-specific T-cells with HLA alloreactivity do not produce GVHD in human subjects. Blood. 2010;116(22):4700–4702.CrossRefGoogle Scholar

Peggs, KS, Verfuerth, S, Pizzey, A, et al. Adoptive cellular therapy for early cytomegalovirus infection after allogeneic stem-cell transplantation with virus-specific T-cell lines. The Lancet. 2003;362(9393):1375–1377.CrossRefGoogle ScholarPubMed

Rooney, CM, Smith, CA, Ng, CY, et al. Infusion of cytotoxic T-cells for the prevention and treatment of Epstein–Barr virus-induced lymphoma in allogeneic transplant recipients. Blood. 1998;92(5):1549–1555.CrossRefGoogle ScholarPubMed

Walter, EA, Greenberg, PD, Gilbert, MJ, et al. Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. N Engl J Med. 1995;333(16):1038–1044.CrossRefGoogle ScholarPubMed

Trivedi, D, Williams, RY, O’Reilly, RJ, Koehne, G. Generation of CMV-specific T lymphocytes using protein-spanning pools of pp65-derived overlapping pentadecapeptides for adoptive immunotherapy. Blood. 2005;105(7):2793–2801.CrossRefGoogle ScholarPubMed

Gerdemann, U, Keirnan, JM, Katari, UL, et al. Rapidly generated multivirus-specific cytotoxic T lymphocytes for the prophylaxis and treatment of viral infections. Mol Ther. 2012;20(8):1622–1632.CrossRefGoogle ScholarPubMed

Hanley, PJC, Melenhorst, J, Scheinberg, P, et al. Naïve T-cell-derived CTL recognize atypical epitopes of CMVpp65 with higher avidity than CMV-seropositive donor-derived CTL – a basis for treatment of post-transplant viral infection by adoptive transfer of T-cells from virus-naïve donors. ISCT 2013 Annual Meeting (Abstract); 2013.CrossRefGoogle Scholar

Berger, C, Jensen, MC, Lansdorp, PM, Gough, M, Elliott, C, Riddell, SR. Adoptive transfer of effector CD8+ T-cells derived from central memory cells establishes persistent T cell memory in primates. J Clin Invest. 2008;118(1):294–305.CrossRefGoogle ScholarPubMed

Willinger, T, Freeman, T, Hasegawa, H, McMichael, AJ, Callan, MF. Molecular signatures distinguish human central memory from effector memory CD8 T cell subsets. J Immunol. 2005;175(9):5895–5903.CrossRefGoogle ScholarPubMed

Janeway, C. Immunobiology: The Immune System in Health and Disease. 6th ed. New York: Garland Science; 2005.Google Scholar

Leen, AM, Rooney, CM, Foster, AE. Improving T cell therapy for cancer. Ann Rev Immunol. 2007;25:243–265.CrossRefGoogle ScholarPubMed

Eshhar, Z. Tumor-specific T-bodies: towards clinical application. Cancer Immunol Immunother. 1997;45(3–4):131–136.CrossRefGoogle ScholarPubMed

Schub, A, Schuster, IG, Hammerschmidt, W, Moosmann, A. CMV-specific TCR-transgenic T cells for immunotherapy. J Immunol. 2009;183(10):6819–6830.CrossRefGoogle ScholarPubMed

Scholten, KB, Turksma, AW, Ruizendaal, JJ, et al. Generating HPV specific T helper cells for the treatment of HPV induced malignancies using TCR gene transfer. J Transl Med. 2011;9:147.CrossRefGoogle ScholarPubMed

Gehring, AJ, Xue, SA, Ho, ZZ, et al. Engineering virus-specific T-cells that target HBV infected hepatocytes and hepatocellular carcinoma cell lines. J Hepatol. 2011;55(1):103–110.CrossRefGoogle ScholarPubMed

Zhang, Y, Liu, Y, Moxley, KM, et al. Transduction of human T-cells with a novel T-cell receptor confers anti-HCV reactivity. PLoS Pathogens. 2010;6(7):e1001018.CrossRefGoogle ScholarPubMed

Luo, W, Zhang, XB, Huang, YT, et al. Development of genetically engineered CD4+ and CD8+ T cells expressing TCRs specific for a M. tuberculosis 38-kDa antigen. J Mol Med (Berl). 2011;89(9):903–913.CrossRefGoogle ScholarPubMed

Oh, HL, Chia, A, Chang, CX, et al. Engineering T-cells specific for a dominant severe acute respiratory syndrome coronavirus CD8 T cell epitope. J Virol. 2011;85(20):10464–10471.CrossRefGoogle ScholarPubMed

Roan, NR, Starnbach, MN. Antigen-specific CD8+ T cells respond to Chlamydia trachomatis in the genital mucosa. J Immunol. 2006;177(11):7974–7979.CrossRefGoogle ScholarPubMed

Ueno, T, Fujiwara, M, Tomiyama, H, Onodera, M, Takiguchi, M. Reconstitution of anti-HIV effector functions of primary human CD8 T lymphocytes by transfer of HIV-specific alphabeta TCR genes. Eur J Immunol. 2004;34(12):3379–3388.CrossRefGoogle ScholarPubMed

Masiero, S, Del Vecchio, C, Gavioli, R, et al. T-cell engineering by a chimeric T-cell receptor with antibody-type specificity for the HIV-1 gp120. Gene Ther. 2005;12(4):299–310.CrossRefGoogle ScholarPubMed

Sahu, GK, Sango, K, Selliah, N, Ma, Q, Skowron, G, Junghans, RP. Anti-HIV designer T-cells progressively eradicate a latently infected cell line by sequentially inducing HIV reactivation then killing the newly gp120-positive cells. Virology. 2013;446(1–2):268–275.CrossRefGoogle ScholarPubMed

Bitton, N, Verrier, F, Debre, P, Gorochov, G. Characterization of T cell-expressed chimeric receptors with antibody-type specificity for the CD4 binding site of HIV-1 gp120. Eur J immunol. 1998;28(12):4177–4187.3.0.CO;2-J>CrossRefGoogle ScholarPubMed

Joseph, A, Zheng, JH, Follenzi, A, et al. Lentiviral vectors encoding human immunodeficiency virus type 1 (HIV-1)-specific T-cell receptor genes efficiently convert peripheral blood CD8 T lymphocytes into cytotoxic T lymphocytes with potent in-vitro and in vivo HIV-1-specific inhibitory activity. J Virol. 2008;82(6):3078–3089.CrossRefGoogle ScholarPubMed

Kumaresan, PR, Manuri, PR, Albert, ND, et al. Bioengineering T cells to target carbohydrate to treat opportunistic fungal infection. Proc Natl Acad Sci USA. 2014;111(29):10660–10665.CrossRefGoogle ScholarPubMed

Cobbold, M, Khan, N, Pourgheysari, B, et al. Adoptive transfer of cytomegalovirus-specific CTL to stem cell transplant patients after selection by HLA-peptide tetramers. J Exp Med. 2005;202(3):379–386.CrossRefGoogle ScholarPubMed

Feuchtinger, T, Opherk, K, Bethge, WA, et al. Adoptive transfer of pp65-specific T-cells for the treatment of chemorefractory cytomegalovirus disease or reactivation after haploidentical and matched unrelated stem cell transplantation. Blood. 2010;116(20):4360–4367.CrossRefGoogle ScholarPubMed

Peggs, KS, Thomson, K, Samuel, E, et al. Directly selected cytomegalovirus-reactive donor T-cells confer rapid and safe systemic reconstitution of virus-specific immunity following stem cell transplantation. Clin Infect Dis. 2011;52(1):49–57.CrossRefGoogle ScholarPubMed

Uhlin, M, Okas, M, Gertow, J, Uzunel, M, Brismar, TB, Mattsson, J. A novel haplo-identical adoptive CTL therapy as a treatment for EBV-associated lymphoma after stem cell transplantation. Cancer Immunol Immunother. 2010;59(3):473–477.CrossRefGoogle ScholarPubMed

Moosmann, A, Bigalke, I, Tischer, J, et al. Effective and long-term control of EBV PTLD after transfer of peptide-selected T cells. Blood. 2010;115(14):2960–2970.CrossRefGoogle ScholarPubMed

Uhlin, M, Gertow, J, Uzunel, M, et al. Rapid salvage treatment with virus-specific T-cells for therapy-resistant disease. Clin Infect Dis. 2012;55(8):1064–1073.CrossRefGoogle ScholarPubMed

Leen, AM, Christin, A, Myers, GD, et al. Cytotoxic T lymphocyte therapy with donor T-cells prevents and treats adenovirus and Epstein–Barr virus infections after haploidentical and matched unrelated stem cell transplantation. Blood. 2009;114(19):4283–4292.CrossRefGoogle ScholarPubMed

Micklethwaite, KP, Clancy, L, Sandher, U, et al. Prophylactic infusion of cytomegalovirus-specific cytotoxic T lymphocytes stimulated with Ad5f35pp65 gene-modified dendritic cells after allogeneic hemopoietic stem cell transplantation. Blood. 2008;112(10):3974–3981.CrossRefGoogle ScholarPubMed

Feuchtinger, T, Matthes-Martin, S, Richard, C, et al. Safe adoptive transfer of virus-specific T-cell immunity for the treatment of systemic adenovirus infection after allogeneic stem cell transplantation. Br J Haematol. 2006;134(1):64–76.CrossRefGoogle ScholarPubMed

Qasim, W, Derniame, S, Gilmour, K, et al. Third-party virus-specific T-cells eradicate adenoviraemia but trigger bystander graft-versus-host disease. Br J Haematol. 2011;154(1):150–153.CrossRefGoogle ScholarPubMed

Blyth, E, Clancy, L, Simms, R, et al. Donor-derived CMV-specific T cells reduce the requirement for CMV-directed pharmacotherapy after allogeneic stem cell transplantation. Blood. 2013;121(18):3745–3758.CrossRefGoogle ScholarPubMed

Vera, JF, Brenner, LJ, Gerdemann, U, et al. Accelerated production of antigen-specific T-cells for preclinical and clinical applications using gas-permeable rapid expansion cultureware (G-Rex). J Immunother. 2010;33(3):305–315.CrossRefGoogle ScholarPubMed

Papadopoulou, A, Gerdemann, U, Katari, UL, et al. Activity of broad-spectrum T cells as treatment for Adv, EBV, CMV, BKV, and HHV6 infections after HSCT. Sci Transl Med. 2014;6(242):242ra283.CrossRefGoogle ScholarPubMed

Lam, S, Bollard, C. T-cell therapies for HIV. Immunotherapy. 2013;5(4):407–414.CrossRefGoogle ScholarPubMed

Lieberman, J, Skolnik, PR, Parkerson, GR, 3rd, et al. Safety of autologous, ex vivo-expanded human immunodeficiency virus (HIV)-specific cytotoxic T-lymphocyte infusion in HIV-infected patients. Blood. 1997;90(6):2196–2206.CrossRefGoogle ScholarPubMed

Deeks, SG, Wagner, B, Anton, PA, et al. A phase II randomized study of HIV-specific T-cell gene therapy in subjects with undetectable plasma viremia on combination antiretroviral therapy. Mol Ther. 2002;5(6):788–797.CrossRefGoogle ScholarPubMed

Mitsuyasu, RT, Anton, PA, Deeks, SG, et al. Prolonged survival and tissue trafficking following adoptive transfer of CD4zeta gene-modified autologous CD4(+) and CD8(+) T-cells in human immunodeficiency virus-infected subjects. Blood. 2000;96(3):785–793.CrossRefGoogle ScholarPubMed

Tebas, P, Stein, D, Binder-Scholl, G, et al. Antiviral effects of autologous CD4 T-cells genetically modified with a conditionally replicating lentiviral vector expressing long antisense to HIV. Blood. 2013;121(9):1524–1533.CrossRefGoogle ScholarPubMed

Tebas, P, Stein, D, Tang, WW, et al. Gene editing of CCR5 in autologous CD4 T cells of persons infected with HIV. New Engl J Med. 2014;370(10):901–910.CrossRefGoogle ScholarPubMed

Didigu, CA, Wilen, CB, Wang, J, et al. Simultaneous zinc-finger nuclease editing of the HIV coreceptors ccr5 and cxcr4 protects CD4+ T-cells from HIV-1 infection. Blood. 2014;123(1):61–69.CrossRefGoogle Scholar

Balduzzi, A, Lucchini, G, Hirsch, HH, et al. Polyomavirus JC-targeted T-cell therapy for progressive multiple leukoencephalopathy in a hematopoietic cell transplantation recipient. Bone Marrow Transplant. 2011;46(7):987–992.CrossRefGoogle Scholar

Ramos, CA, Narala, N, Vyas, GM, et al. Human papillomavirus type 16 E6/E7-specific cytotoxic T lymphocytes for adoptive immunotherapy of HPV-associated malignancies. J Immunother. 2013;36(1):66–76.CrossRefGoogle ScholarPubMed

Cruz, CR, Hanley, PJ, Liu, H, et al. Adverse events following infusion of T cells for adoptive immunotherapy: a 10-year experience. Cytotherapy. 2010;12(6):743–749.CrossRefGoogle ScholarPubMed

Haque, T, Taylor, C, Wilkie, GM, et al. Complete regression of posttransplant lymphoproliferative disease using partially HLA-matched Epstein Barr virus-specific cytotoxic T-cells. Transplantation. 2001;72(8):1399–1402.CrossRefGoogle ScholarPubMed

Haque, T, Wilkie, GM, Taylor, C, et al. Treatment of Epstein–Barr-virus-positive post-transplantation lymphoproliferative disease with partly HLA-matched allogeneic cytotoxic T-cells. Lancet. 2002;360(9331):436–442.CrossRefGoogle ScholarPubMed

Haque, T, Wilkie, GM, Jones, MM, et al. Allogeneic cytotoxic T-cell therapy for EBV-positive posttransplantation lymphoproliferative disease: results of a phase 2 multicenter clinical trial. Blood. 2007;110(4):1123–1131.CrossRefGoogle ScholarPubMed

Barker, JN, Doubrovina, E, Sauter, C, et al. Successful treatment of EBV-associated posttransplantation lymphoma after cord blood transplantation using third-party EBV-specific cytotoxic T lymphocytes. Blood. 2010;116(23):5045–5049.CrossRefGoogle ScholarPubMed

Leen, AM, Bollard, CM, Mendizabal, AM, et al. Multicenter study of banked third-party virus-specific T cells to treat severe viral infections after hematopoietic stem cell transplantation. Blood. 2013;121(26):5113–5123.CrossRefGoogle ScholarPubMed

Wy Ip, W, Qasim, W. Management of adenovirus in children after allogeneic hematopoietic stem cell transplantation. Adv Hematol. 2013;2013:176418.CrossRefGoogle ScholarPubMed

Schub, A, Schuster, IG, Hammerschmidt, W, Moosmann, A. CMV-specific TCR-transgenic T-cells for immunotherapy. J Immunol. 2009;183(10):6819–6830.CrossRefGoogle ScholarPubMed

Xue, SA, Gao, L, Ahmadi, M, et al. Human MHC Class I-restricted high avidity CD4 T-cells generated by co-transfer of TCR and CD8 mediate efficient tumor rejection in vivo. Oncoimmunology. 2013;2(1):e22590.CrossRefGoogle ScholarPubMed

Frumento, G, Zheng, Y, Aubert, G, et al. Cord blood T cells retain early differentiation phenotype suitable for immunotherapy after TCR gene transfer to confer EBV specificity. Am J Transplant. 2013;13(1):45–55.CrossRefGoogle ScholarPubMed

Basso, S, Zecca, M, Calafiore, L, et al. Successful treatment of a classic Hodgkin lymphoma-type post-transplant lymphoproliferative disorder with tailored chemotherapy and Epstein–Barr virus-specific cytotoxic T lymphocytes in a pediatric heart transplant recipient. Pediatr Transplant. 2013;17(7):E168–173.CrossRefGoogle Scholar

Haque, T, Amlot, PL, Helling, N, et al. Reconstitution of EBV-specific T cell immunity in solid organ transplant recipients. J Immunol. 1998;160(12):6204–6209.CrossRefGoogle ScholarPubMed

Savoldo, B, Goss, J, Liu, Z, et al. Generation of autologous Epstein–Barr virus-specific cytotoxic T-cells for adoptive immunotherapy in solid organ transplant recipients. Transplantation. 2001;72(6):1078–1086.CrossRefGoogle ScholarPubMed

Romani, L. Immunity to fungal infections. Nat Rev Immunol. 2004;4(1):1–23.CrossRefGoogle ScholarPubMed

Groll, AH, McNeil, Grist L. Current challenges in the diagnosis and management of invasive fungal infections: report from the 15th International Symposium on Infections in the Immunocompromised Host: Thessaloniki, Greece, 22–25 June 2008. Int J Antimicrob Agents. 2009;33(2):101–104.CrossRefGoogle ScholarPubMed

Milner, JD, Holland, SM. The cup runneth over: lessons from the ever-expanding pool of primary immunodeficiency diseases. Nat Rev Immunol. 2013;13(9):635–648.CrossRefGoogle ScholarPubMed

Kim, CJ, McKinnon, LR, Kovacs, C, et al. Mucosal Th17 cell function is altered during HIV infection and is an independent predictor of systemic immune activation. J Immunol. 2013;191(5):2164–2173.CrossRefGoogle ScholarPubMed

Cruz, CR, Lam, S, Hanley, PJ, et al. Robust T cell responses to aspergillosis in chronic granulomatous disease: implications for immunotherapy. Clin Exp Immunol. 2013;174(1):89–96.CrossRefGoogle Scholar

Beck, O, Topp, MS, Koehl, U, et al. Generation of highly purified and functionally active human TH1 cells against Aspergillus fumigatus. Blood. 2006;107(6):2562–2569.CrossRefGoogle ScholarPubMed

Tramsen, L, Schmidt, S, Boenig, H, et al. Clinical-scale generation of multi-specific anti-fungal T cells targeting Candida, Aspergillus and mucormycetes. Cytotherapy. 2013;15(3):344–351.CrossRefGoogle ScholarPubMed

Khanna, N, Stuehler, C, Conrad, B, et al. Generation of a multipathogen-specific T-cell product for adoptive immunotherapy based on activation-dependent expression of CD154. Blood. 2011;118(4):1121–1131.CrossRefGoogle ScholarPubMed

Gomez, MJ, Maras, B, Barca, A, La Valle, R, Barra, D, Cassone, A. Biochemical and immunological characterization of MP65, a major mannoprotein antigen of the opportunistic human pathogen Candida albicans. Infect Immun. 2000;68(2):694–701.CrossRefGoogle Scholar

Jolink, H, Meijssen, IC, Hagedoorn, RS, et al. Characterization of the T-cell-mediated immune response against the Aspergillus fumigatus proteins Crf1 and catalase 1 in healthy individuals. J Infect Dis. 2013;208(5):847–856.CrossRefGoogle ScholarPubMed

Schmidt, S, Tramsen, L, Perkhofer, S, et al. Characterization of the cellular immune responses to Rhizopus oryzae with potential impact on immunotherapeutic strategies in hematopoietic stem cell transplantation. J Infect Dis. 2012;206(1):135–139.CrossRefGoogle ScholarPubMed

Tramsen, L, Beck, O, Schuster, FR, et al. Generation and characterization of anti-Candida T-cells as potential immunotherapy in patients with Candida infection after allogeneic hematopoietic stem-cell transplant. J Infect Dis. 2007;196(3):485–492.CrossRefGoogle ScholarPubMed

Goodridge, HS, Wolf, AJ, Underhill, DM. Beta-glucan recognition by the innate immune system. Immunol Rev. 2009;230(1):38–50.CrossRefGoogle ScholarPubMed

Perruccio, K, Tosti, A, Burchielli, E, et al. Transferring functional immune responses to pathogens after haploidentical hematopoietic transplantation. Blood. 2005;106(13):4397–4406.CrossRefGoogle ScholarPubMed

De Angelis, B, Dotti, G, Quintarelli, C, et al. Generation of Epstein–Barr virus-specific cytotoxic T lymphocytes resistant to the immunosuppressive drug tacrolimus (FK506). Blood. 2009;114(23):4784–4791.CrossRefGoogle Scholar

Brewin, J, Mancao, C, Straathof, K, et al. Generation of EBV-specific cytotoxic T cells that are resistant to calcineurin inhibitors for the treatment of posttransplantation lymphoproliferative disease. Blood. 2009;114(23):4792–4803.CrossRefGoogle ScholarPubMed

Vera, JF, Brenner, LJ, Gerdemann, U, et al. Accelerated production of antigen-specific T-cells for preclinical and clinical applications using gas-permeable rapid expansion cultureware (G-Rex). J Immunother. 2010;33(3):305–315.CrossRefGoogle ScholarPubMed

Gattinoni, L, Lugli, E, Ji, Y, et al. A human memory T cell subset with stem cell-like properties. Nat Med. 2011;17(10):1290–1297.CrossRefGoogle ScholarPubMed

Williams, DM, Weiner, MH, Drutz, DJ. Immunologic studies of disseminated infection with Aspergillus fumigatus in the nude mouse. J Infect Dis. 1981;143(5):726–733.CrossRefGoogle ScholarPubMed

Holding, KJ, Dworkin, MS, Wan, PC, et al. Aspergillosis among people infected with human immunodeficiency virus: incidence and survival. Adult and Adolescent Spectrum of HIV Disease Project. Clin Infect Dis. 2000;31(5):1253–1257.CrossRefGoogle ScholarPubMed

Zelante, T, De Luca, A, Bonifazi, P, et al. IL-23 and the Th17 pathway promote inflammation and impair antifungal immune resistance. Eur J Immunol. 2007;37(10):2695–2706.CrossRefGoogle ScholarPubMed

Werner, JL, Gessner, MA, Lilly, LM, et al. Neutrophils produce interleukin 17A (IL-17A) in a dectin-1- and IL-23-dependent manner during invasive fungal infection. Infect Immun. 2011;79(10):3966–3977.CrossRefGoogle Scholar

Marr, KA, Carter, RA, Boeckh, M, Martin, P, Corey, L. Invasive aspergillosis in allogeneic stem cell transplant recipients: changes in epidemiology and risk factors. Blood. 2002;100(13):4358–4366.CrossRefGoogle ScholarPubMed

Zimmerli, W, Zarth, A, Gratwohl, A, Speck, B. Neutrophil function and pyogenic infections in bone marrow transplant recipients. Blood. 1991;77(2):393–399.CrossRefGoogle ScholarPubMed

Cobbold, M, Khan, N, Pourgheysari, B, et al. Adoptive transfer of cytomegalovirus-specific CTL to stem cell transplant patients after selection by HLA-peptide tetramers. J Exp Med. 2005;202(3):379–386.CrossRefGoogle ScholarPubMed

Peggs, KS, Thomson, K, Samuel, E, et al. Directly selected cytomegalovirus-reactive donor T cells confer rapid and safe systemic reconstitution of virus-specific immunity following stem cell transplantation. Clin Infect Dis. 2011;52(1):49–57.CrossRefGoogle ScholarPubMed

Uhlin, M, Okas, M, Gertow, J, Uzunel, M, Brismar, TB, Mattsson, J. A novel haplo-identical adoptive CTL therapy as a treatment for EBV-associated lymphoma after stem cell transplantation. Cancer Immunol Immunother. 2010;59(3):473–477.CrossRefGoogle ScholarPubMed

Qasim, W, Derniame, S, Gilmour, K, et al. Third-party virus-specific T-cells eradicate adenoviraemia but trigger bystander graft-versus-host disease. Br J Haematol. 2011;154(1):150–153.CrossRefGoogle ScholarPubMed

Feuchtinger, T, Matthes-Martin, S, Richard, C, et al. Safe adoptive transfer of virus-specific T-cell immunity for the treatment of systemic adenovirus infection after allogeneic stem cell transplantation. Br J Haematol. 2006;134(1):64–76.CrossRefGoogle ScholarPubMed

Balduzzi, A, Lucchini, G, Hirsch, HH, et al. Polyomavirus JC-targeted T-cell therapy for progressive multiple leukoencephalopathy in a hematopoietic cell transplantation recipient. Bone Marrow Transplant. 2011;46(7):987–992.CrossRefGoogle Scholar

Uhlin, M, Gertow, J, Uzunel, M, et al. Rapid salvage treatment with virus-specific T cells for therapy-resistant disease. Clin Infect Dis. 2012;55(8):1064–1073.CrossRefGoogle ScholarPubMed

Leen, AM, Myers, GD, Sili, U, et al. Monoculture-derived T lymphocytes specific for multiple viruses expand and produce clinically relevant effects in immunocompromised individuals. Nat Med. 2006;12(10):1160–1166.CrossRefGoogle ScholarPubMed

Gerdemann, U, Katari, UL, Papadopoulou, A, et al. Safety and clinical efficacy of rapidly-generated trivirus-directed T-cells as treatment for adenovirus, EBV, and CMV infections after allogeneic hematopoietic stem cell transplant. Mol Ther. 2013;21(11):2113–2121.CrossRefGoogle ScholarPubMed

Tramsen, L, Koehl, U, Tonn, T, et al. Clinical-scale generation of human anti-Aspergillus T-cells for adoptive immunotherapy. Bone Marrow Transplant. 2009;43(1):13–19.CrossRefGoogle ScholarPubMed

Gaundar, SS, Clancy, L, Blyth, E, Meyer, W, Gottlieb, DJ. Robust polyfunctional T-helper 1 responses to multiple fungal antigens from a cell population generated using an environmental strain of Aspergillus fumigatus. Cytotherapy. 2012;14(9):1119–1130.CrossRefGoogle ScholarPubMed

Stuehler, C, Khanna, N, Bozza, S, et al. Cross-protective TH1 immunity against Aspergillus fumigatus and Candida albicans. Blood. 2011;117(22):5881–5891.CrossRefGoogle ScholarPubMed

Jolink, H, Meijssen, IC, Hagedoorn, RS, et al. Characterization of the T-cell-mediated immune response against the Aspergillus fumigatus proteins Crf1 and catalase 1 in healthy individuals. J Infect Dis. 2013;208(5):847–856.CrossRefGoogle ScholarPubMed

Feng, CG, Britton, WJ. CD4+ and CD8+ T cells mediate adoptive immunity to aerosol infection of Mycobacterium bovis bacillus Calmette-Guerin. J Infect Dis. 2000;181(5):1846–1849.CrossRefGoogle ScholarPubMed

Stemberger, C, Graef, P, Odendahl, M, et al. Lowest numbers of primary CD8(+) T cells can reconstitute protective immunity upon adoptive immunotherapy. Blood. 2014;124(4):628–637.CrossRefGoogle ScholarPubMed

Bhadra, R, Cobb, DA, Khan, IA. Donor CD8+ T cells prevent Toxoplasma gondii de-encystation but fail to rescue the exhausted endogenous CD8+ T cell population. Infect Immun. 2013;81(9):3414–3425.CrossRefGoogle ScholarPubMed

Polley, R, Stager, S, Prickett, S, et al. Adoptive immunotherapy against experimental visceral leishmaniasis with CD8+ T cells requires the presence of cognate antigen. Infect Immun. 2006;74(1):773–776.CrossRefGoogle ScholarPubMed

Naik, S, Nicholas, SK, Martinez, CA, et al., Adoptive immunotherapy for primary immunodeficiency disorders with virus-specific T lymphocytes. J Allergy Clin Immunol. 2016;137(5):1498–505.CrossRefGoogle ScholarPubMed

Henrickson, KJ. Parainfluenza viruses. Clin Microbiol Rev. 2003;16(2):242–64.CrossRefGoogle ScholarPubMed

Nichols, WG, Corey, L, Gooley, T, et al. Parainfluenza virus infections after hematopoietic stem cell transplantation: risk factors, response to antiviral therapy, and effect on transplant outcome. Blood. 2001;98(3):573–8.CrossRefGoogle ScholarPubMed

McLaughlin, L, Lang, H, Williams, E, et al. Human parainfluenza virus-3 can be targeted by rapidly ex vivo expanded T lymphocytes. Cytotherapy. 2016;18(12):1515–24.CrossRefGoogle ScholarPubMed